# ACOG catalysts: Alpha Cognition Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/acog/catalysts

> Alpha Cognition Inc. (ACOG) has no upcoming catalysts in this calendar. The latest recorded is the Alpha Cognition Inc. earnings report, March 25, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Alpha Cognition Inc. |
| Ticker | ACOG (Nasdaq) |
| SEC CIK | 1655923 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/acog |

## Cash runway

Cash $37.8M as of 2026-09-30; quarterly burn $4.8M; about 23.4 months of runway at that rate (XBRL company facts, accession 0001213900-26-118702).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 7, 2023 | [ZUNVEYL (benzgalantamine) NDA/BLA acceptance](https://sec-api.dev/pdufa/benzgalantamine) | ACOG |  | completed | "On December 7, 2023, the Company announced that the FDA accepted the Company's new drug application NDA for ZUNVEYL formerly ALPHA-1062 and has granted a PDUFA goal date of July 27, 2024." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm)) |
| July 26, 2024 | [Alpha Cognition Inc. FDA approval](https://sec-api.dev/companies/acog/catalysts) | ACOG |  | completed, approved | "On July 26, 2024, the Company received approval by the FDA of the Company's" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1655923/000121390025026225/ea0233390-10k_alpha.htm)) |
| July 26, 2024 | [Zunveyl (benzgalantamine gluconate) FDA approval](https://sec-api.dev/pdufa/benzgalantamine-gluconate) | ACOG |  | completed, approved | "NDA218549 ORIG-1 (Type 2 - New Active Ingredient and Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240726, review_priority STANDARD; sponsor_name ALPHA COGNITION; product ZUNVEYL (BENZGALANTAMINE GLUCONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218549%22)) |
| July 27, 2024 | [ZUNVEYL (benzgalantamine) PDUFA date](https://sec-api.dev/pdufa/benzgalantamine) | ACOG |  | completed, approved | "On December 7, 2023, the Company announced that the FDA accepted the Company's new drug application NDA for ZUNVEYL formerly ALPHA-1062 and has granted a PDUFA goal date of July 27, 2024." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm)) |
| July 29, 2024 | [ZUNVEYL (benzgalantamine) FDA approval](https://sec-api.dev/pdufa/benzgalantamine) | ACOG | mild-to-moderate Alzheimer's disease | completed, approved | "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration ("FDA") for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655923/000121390025110061/ea0263490-10q_alpha.htm)) |
| March 25, 2026 | [Alpha Cognition Inc. earnings report](https://sec-api.dev/companies/acog/catalysts) | ACOG |  | completed | "PRESS RELEASE ANNOUNCES FINANCIAL RESULTS FOR THE 2025 FISCAL YEAR DATED MARCH 26, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655923/000121390026034778/ea028362201ex99-1.htm)) |

## Drugs

- [ZUNVEYL (benzgalantamine)](https://sec-api.dev/pdufa/benzgalantamine): mild-to-moderate alzheimer's disease, mild to moderate dementia of the alzheimer's type in adults
- [Zunveyl (benzgalantamine gluconate)](https://sec-api.dev/pdufa/benzgalantamine-gluconate): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/acog/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ACOG catalysts: Alpha Cognition Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/acog/catalysts

```bibtex
@misc{secapidev_companies_acog_catalysts_20261116,
  title        = {ACOG catalysts: Alpha Cognition Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/acog/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_acog_catalysts_20261116","title":"ACOG catalysts: Alpha Cognition Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/acog/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
